Brain Research Center Zwolle B.V. — Clinical Trial Site

21 Registered trials

10 Currently recruiting

Organisation

Brain Research Center Zwolle B.V.

Location

Zwolle, Netherlands

Identifier

ORG-100043389

Address

Dokter Stolteweg 90, 8025 AZ, Netherlands

Departments

-
Alzheimer centra
Brain center
Brain Research Center
Brain Research Center Zwole
Brain Research Center Zwolle
Brain Research Center Zwolle / Isala Kliniek
Brain Research centrum
Locatie Zwolle
MDL
N/A
NA
Neurology
Research

Clinical trials at this site (21)

Search interface

Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Recruiting

2022-503148-41-00 Alzheimer's disease 4 2023-12-01
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Diseas… Recruiting

2025-523515-11-00 Early Alzheimer's Disease 1 2026-04-03
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Recruiting

2025-522674-36-00 Metabolic Dysfunction-Associated Steatotic Liver Diseas 5 2026-03-24
A clinical trial to learn about the effects of VHB937 in people with Alzheimer's disease Recruiting

2024-516966-12-00 Alzheimer’s disease 4 2026-02-13
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-12
A Phase 3 Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer’s Disease Recruiting

2025-520747-32-00 Mild to moderate Alzheimer’s Disease 5 2025-10-29
EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure… Recruiting

2025-521188-11-00 Type 2 diabetes 5 2025-10-15
A clinical study of MK-2214 in people with Alzheimer’s disease (MK-2214-004) Recruiting

2024-519190-19-00 Alzheimer’s Disease 4 2025-10-03
A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s dise… Recruiting

2024-511110-21-00 Parkinson’s Disease 1 2024-09-09
A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei… Ended

2023-508306-15-00 Alzheimer’s Disease 5 2024-06-26
GSK4527226 Open-label Extension Study in Patients with Early Alzheimer's Disease. Ended

2025-521107-42-00 Alzheimer's Disease 4 2025-11-25
A Phase 2 Randomized, Placebo-Controlled, Double-Blind, Parallel-group Study to Evaluate the Efficacy and Safety of MK-1167 as Adjunctive Th… Ended

2024-515539-31-00 Alzheimer’s disease dementia 4 2025-04-01
EFFICACY AND SAFETY OF GSK4527226 [AL101] IN PATIENTS WITH EARLY ALZHEIMER’S DISEASE Ended

2023-505083-11-01 Alzheimer's Disease 4 2024-05-07
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB) Ended

2023-504373-20-00 Subjects aged ≥55 years with probable Dementia with Lew 4 2023-08-09
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants … Ended

2023-505645-12-00 Parkinson's Disease 4 2022-11-28
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Prospective, 52-Week, Phase 2 Clinical Study to Evaluate the S… Ended

2024-511610-20-00 Alzheimer's Disease 4 2022-11-08
A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants with Early Idiopathic Pa… Ended

2023-504412-14-00 Early Idiopathic Parkinson’s Disease (PD) 3 2022-09-01
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study with a Long-Term Extension Treatment Period to Assess the … Ended

2022-501188-42-00 Early Alzheimer's Disease 4 2021-04-15
A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease Ended

2023-507303-55-00 Alzheimer Disease 4 2020-09-30
A study to assess how ALZ-801 affects laboratory tests and symptoms of Alzheimer's disease in patients who have a specific genotype (APOE4). Ended

2024-515858-25-00 Subjects with a clinical diagnosis of Alzheimer's disea 4 2020-09-30